The Power of ctDNA Testing in Therapy Selection and Recurrence Monitoring
April 18, 2023 @ 10:00 am – 11:00 am EDT
Spotlight Theater C | Presented by Labcorp Oncology
Moderator: Dr. Mark Sausen, PhD
Presenter: Dr. Mohamad Khasawneh, MD
Leonard Lawson Cancer Center/Pikeville Medical Center
Liquid biopsy represents a transformation in the management of oncology patients given its potential to detect, characterize, and monitor cancers earlier than can be achieved with conventional modalities. Additional value lies in its non-invasive nature, availability and accessibility, which enables other sampling options when tissue is not available or insufficient.
In this symposium, we demonstrate the following:
- The utility of an NGS-based ctDNA testing approach for therapy selection in advanced cancers
- Tissue-agnostic treatment response monitoring in patients with metastatic colorectal cancer and its prognostic value in guiding treatment decisions
This Exhibitor Spotlight Theater is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Spotlight Theater and opinions expressed by presenters are those of the sponsor or presenter and are not of the American Association for Cancer Research® (AACR).